ENDOTHELIN-1 AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AS MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CORONARY HEART DISEASE (CHD), INCLUDING THOSE WHO HAVE SURVIVED NEW CORONAVIRUS INFECTION (COVID-19)

Bolgov Daniil Yurievich, Kuznetsov Sergey Ivanovich, Tkachenko Maxim Sergeevich

The article presents a modern view of the significance of two of the most important markers of endothelial dysfunction - endothelin-1 and vascular endothelial growth factor. The antagonism of the effects of the vasoconstrictor endothelin-1 and the vasodilator, which is critical in maintaining proper vascular tone, nitric oxide, their mutual influence and effect on the vasomotor function of the endothelium is shown. Using the example of a method for quantitative determination of the concentration of endothelin-1, using an enzyme-linked immunosorbent assay, in the plasma of patients diagnosed with coronary heart disease, as well as a laboratory-confirmed diagnosis of coronavirus infection caused by the SARS-CoV-2 virus (COVID-19), the possibility of predicting additional risks is shown cardiovascular complications in this group of patients. The topic under consideration will be of interest to cardiologists, therapists, as well as specialists in other related fields. The issues covered by the authors in this work require further in-depth study.

Keywords:endothelial dysfunction, markers of endothelial dysfunction, endothelial damage, endothelin-1, vascular endothelial growth factor (VEGF), coronary heart disease (CHD), SARS-CoV-2 (COVID-19).